Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Cardiology, Aarhus, Aarhus University Hospital, Aarhus, Denmark.
JAMA Cardiol. 2023 Jul 1;8(7):631-639. doi: 10.1001/jamacardio.2023.1177.
Patients with left main coronary artery disease presenting with an acute coronary syndrome (ACS) represent a high-risk and understudied subgroup of patients with atherosclerosis.
To assess clinical outcomes after PCI vs CABG in patients with left main disease with vs without ACS.
DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from 4 trials comparing PCI with drug-eluting stents vs CABG in patients with left main disease who were considered equally suitable candidates for either strategy (SYNTAX, PRECOMBAT, NOBLE, and EXCEL). Patients were categorized as presenting with or without ACS. Kaplan-Meier event rates through 5 years and Cox model hazard ratios were generated, and interactions were tested. Patients were enrolled in the individual trials from 2004 through 2015. Individual patient data from the trials were pooled and reconciled from 2020 to 2021, and the analyses pertaining to the ACS subgroup were performed from March 2022 through February 2023.
The primary outcome was death through 5 years. Secondary outcomes included cardiovascular death, spontaneous myocardial infarction (MI), procedural MI, stroke, and repeat revascularization.
Among 4394 patients (median [IQR] age, 66 [59-73] years; 3371 [76.7%] male and 1022 [23.3%] female) randomized to receive PCI or CABG, 1466 (33%) had ACS. Patients with ACS were more likely to have diabetes, prior MI, left ventricular ejection fraction less than 50%, and higher SYNTAX scores. At 30 days, patients with ACS had higher all-cause death (hazard ratio [HR], 3.40; 95% CI, 1.81-6.37; P < .001) and cardiovascular death (HR, 3.21; 95% CI, 1.69-6.08; P < .001) compared with those without ACS. Patients with ACS also had higher rates of spontaneous MI (HR, 1.70; 95% CI, 1.25-2.31; P < .001) through 5 years. The rates of all-cause mortality through 5 years with PCI vs CABG were 10.9% vs 11.5% (HR, 0.93; 95% CI, 0.68-1.27) in patients with ACS and 11.3% vs 9.6% (HR, 1.19; 95% CI, 0.95-1.50) in patients without ACS (P = .22 for interaction). The risk of early stroke was lower with PCI vs CABG (ACS: HR, 0.39; 95% CI, 0.12-1.25; no ACS: HR, 0.35; 95% CI, 0.16-0.75), whereas the 5-year risks of spontaneous MI and repeat revascularization were higher with PCI vs CABG (spontaneous MI: ACS: HR, 1.74; 95% CI, 1.09-2.77; no ACS: HR, 3.03; 95% CI, 1.94-4.72; repeat revascularization: ACS: HR, 1.57; 95% CI, 1.19-2.09; no ACS: HR, 1.90; 95% CI, 1.54-2.33), regardless of ACS status.
Among largely stable patients undergoing left main revascularization and with predominantly low to intermediate coronary anatomical complexity, those with ACS had higher rates of early death. Nonetheless, rates of all-cause mortality through 5 years were similar with PCI vs CABG in this high-risk subgroup. The relative advantages and disadvantages of PCI vs CABG in terms of early stroke and long-term spontaneous MI and repeat revascularization were consistent regardless of ACS status.
ClinicalTrials.gov Identifiers: NCT00114972, NCT00422968, NCT01496651, NCT01205776.
患有急性冠状动脉综合征(ACS)的左主干冠状动脉疾病患者代表了动脉粥样硬化的一个高风险和研究不足的亚组。
评估经皮冠状动脉介入治疗(PCI)与冠状动脉旁路移植术(CABG)治疗左主干疾病伴或不伴 ACS 患者的临床结局。
设计、地点和参与者:数据来自 4 项比较左主干疾病患者 PCI 与药物洗脱支架与 CABG 的试验(SYNTAX、PRECOMBAT、NOBLE 和 EXCEL)。将患者分为伴或不伴 ACS。通过 5 年的 Kaplan-Meier 事件率和 Cox 模型风险比生成,并进行交互测试。患者于 2004 年至 2015 年在各个试验中入组。来自试验的个体患者数据于 2020 年至 2021 年进行了汇总和协调,2022 年 3 月至 2023 年 2 月进行了关于 ACS 亚组的分析。
主要终点为 5 年内的死亡。次要终点包括心血管死亡、自发性心肌梗死(MI)、手术性 MI、卒中和再次血运重建。
在 4394 名(中位数[IQR]年龄,66[59-73]岁;3371 名[76.7%]男性和 1022 名[23.3%]女性)随机接受 PCI 或 CABG 治疗的患者中,1466 名(33%)患有 ACS。ACS 患者更有可能患有糖尿病、既往心肌梗死、左心室射血分数低于 50%和更高的 SYNTAX 评分。在 30 天时,ACS 患者的全因死亡率(风险比[HR],3.40;95%CI,1.81-6.37;P<0.001)和心血管死亡率(HR,3.21;95%CI,1.69-6.08;P<0.001)均高于无 ACS 患者。ACS 患者在 5 年内自发性 MI 的发生率也更高(HR,1.70;95%CI,1.25-2.31;P<0.001)。ACS 患者中,PCI 与 CABG 的 5 年全因死亡率分别为 10.9%和 11.5%(HR,0.93;95%CI,0.68-1.27),无 ACS 患者分别为 11.3%和 9.6%(HR,1.19;95%CI,0.95-1.50)(P=0.22 用于交互检验)。与 CABG 相比,PCI 的早期卒中风险较低(ACS:HR,0.39;95%CI,0.12-1.25;无 ACS:HR,0.35;95%CI,0.16-0.75),而 5 年自发性 MI 和再次血运重建的风险较高(自发性 MI:ACS:HR,1.74;95%CI,1.09-2.77;无 ACS:HR,3.03;95%CI,1.94-4.72;再次血运重建:ACS:HR,1.57;95%CI,1.19-2.09;无 ACS:HR,1.90;95%CI,1.54-2.33),无论 ACS 状态如何。
在接受左主干血运重建的患者中,左主干疾病患者大多稳定,且主要为低至中度冠状动脉解剖复杂性,ACS 患者的早期死亡率较高。尽管如此,ACS 亚组患者的 5 年全因死亡率与 PCI 与 CABG 相似。在早期卒中和长期自发性 MI 和再次血运重建方面,PCI 与 CABG 的相对优势和劣势在无论 ACS 状态如何,都是一致的。
ClinicalTrials.gov 标识符:NCT00114972、NCT00422968、NCT01496651、NCT01205776。